Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00300612 | Vaccine Treatment for Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | 6 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors(D-1MT) | terminated | Phase 1 | 17 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03674502 | Safety of ADU-1604 in Adults With Metastatic Melanoma | terminated | Phase 1 | 4 | Aduro Biotech, Inc.INDUSTRY | 2 | May 26, 2020 | clinicaltrials |
| NCT03565406 | A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | terminated | Phase 1 | 11 | NYU Langone HealthOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT03580382 | Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma | terminated | Phase 1 / Phase 2 | 3 | NYU Langone HealthOTHER | 1 | May 20, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT02385669 | A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma(Mel62; 6PAC) | terminated | Phase 1 / Phase 2 | 3 | Craig L Slingluff, JrOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02516527 | A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors | completed | Phase 1 | 25 | Bristol-Myers SquibbINDUSTRY | 1 | May 1, 2020 | clinicaltrials |
| NCT04072900 | A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma | unknown | Phase 1 | 30 | Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT01916135 | PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative | completed | Phase 1 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2020 | clinicaltrials |
| NCT02285101 | Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors | completed | Phase 1 | 23 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT04357509 | The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma | unknown | Phase 1 | 32 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT03002376 | An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) | completed | Phase 1 | 47 | Regeneron PharmaceuticalsINDUSTRY | 4 | Apr 20, 2020 | clinicaltrials |
| NCT01103635 | Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma | completed | Phase 1 | 25 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02180061 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) | completed | Phase 1 | 42 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 31, 2020 | clinicaltrials |
| NCT02968680 | Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma | terminated | Phase 1 | 5 | University of Southern CaliforniaOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT00118313 | Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | completed | Phase 1 | — | Craig L Slingluff, JrOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT02354690 | Vemurafenib and TIL Therapy for Metastatic Melanoma | completed | Phase 1 / Phase 2 | 13 | Inge Marie SvaneOTHER | 1 | Mar 23, 2020 | clinicaltrials |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | completed | Phase 1 | 190 | PfizerINDUSTRY | 5 | Mar 17, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT01313429 | Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum | terminated | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2020 | clinicaltrials |
| NCT04274816 | Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma | completed | Phase 1 | 13 | A.J.M. van den EertweghOTHER | 0 | Feb 18, 2020 | clinicaltrials |
| NCT02608034 | A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State | completed | Phase 1 | 32 | Genentech, Inc.INDUSTRY | 4 | Feb 12, 2020 | clinicaltrials |
| NCT03052205 | A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors(ILLUMINATE-101) | completed | Phase 1 | 54 | Idera Pharmaceuticals, Inc.INDUSTRY | 2 | Feb 11, 2020 | clinicaltrials |
| NCT04125719 | PVSRIPO in Combination With Nivolumab in Melanoma(PPD1) | withdrawn | Phase 1 | 0 | Darell BignerOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02379195 | Peginterferon and TIL Therapy for Metastatic Melanoma | completed | Phase 1 / Phase 2 | 12 | Inge Marie SvaneOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03159117 | Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma | completed | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01684241 | RBL001/RBL002 Phase I Clinical Trial(MERIT) | completed | Phase 1 | 29 | BioNTech RNA Pharmaceuticals GmbHINDUSTRY | 2 | Jan 18, 2020 | clinicaltrials |
| NCT02035956 | IVAC MUTANOME Phase I Clinical Trial | completed | Phase 1 | 15 | BioNTech RNA Pharmaceuticals GmbHINDUSTRY | 2 | Jan 18, 2020 | clinicaltrials |
| NCT02424916 | Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study(MelSort) | completed | Phase 1 / Phase 2 | 7 | Nantes University HospitalOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT02014116 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body | terminated | Phase 1 | 51 | Eli Lilly and CompanyINDUSTRY | 4 | Dec 27, 2019 | clinicaltrials |
| NCT04206358 | Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma | unknown | Phase 1 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT02676869 | Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma(TACTI-mel) | completed | Phase 1 | 24 | Immutep Australia Pty. Ltd.INDUSTRY | 1 | Dec 18, 2019 | clinicaltrials |
| NCT01336985 | Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads | terminated | Phase 1 | 5 | National Institutes of Health Clinical Center (CC)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00145041 | Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction | completed | Phase 1 | 7 | Acrotech Biopharma Inc.INDUSTRY | 1 | Dec 12, 2019 | clinicaltrials |
| NCT00304460 | Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer | completed | Phase 1 | 138 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT01218867 | CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04180774 | Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer | completed | Phase 1 / Phase 2 | 80 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT01585415 | Vemurafenib and White Blood Cell Therapy for Advanced Melanoma | terminated | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00003897 | Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma | completed | Phase 1 | 18 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01196416 | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma | completed | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Nov 18, 2019 | clinicaltrials |
| NCT01021059 | A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01213472 | Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma | completed | Phase 1 | 33 | GlaxoSmithKlineINDUSTRY | 8 | Oct 9, 2019 | clinicaltrials |
| NCT03982134 | PDR001 + Panobinostat for Melanoma and NSCLC | withdrawn | Phase 1 | 0 | Muhammad FurqanOTHER | 0 | Oct 4, 2019 | clinicaltrials |
Data updated 23 days agoSource updated May 28, 2020source: clinicaltrials